Trubion Pharmaceuticals, a developer of novel drugs to treat rheumatoid arthritis and systemic lupus erythematosus, priced 4.0 million shares at $13, the low end of its proposed $13 to $15 range. Morgan Stanley was the lead manager on the deal. Expect the stock to begin trading this morning on the NASDAQ under the symbol "TRBN."
